Wimmer Associates 1 LLC Buys 815 Shares of Eli Lilly and Company (NYSE:LLY)

Wimmer Associates 1 LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 58.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,200 shares of the company's stock after purchasing an additional 815 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Wimmer Associates 1 LLC's holdings, making the stock its 29th biggest position. Wimmer Associates 1 LLC's holdings in Eli Lilly and Company were worth $1,698,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of LLY. Triglav Skladi D.O.O. bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at $42,884,000. Twinbeech Capital LP acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $62,077,000. Two Sigma Advisers LP increased its stake in Eli Lilly and Company by 49.7% in the fourth quarter. Two Sigma Advisers LP now owns 802,400 shares of the company's stock valued at $619,453,000 after acquiring an additional 266,400 shares during the last quarter. Two Sigma Investments LP boosted its stake in Eli Lilly and Company by 61.6% in the fourth quarter. Two Sigma Investments LP now owns 322,690 shares of the company's stock valued at $249,117,000 after buying an additional 122,954 shares in the last quarter. Finally, Texas Bank & Trust Co bought a new position in Eli Lilly and Company in the fourth quarter valued at about $3,664,000. 82.53% of the stock is owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 3.3%

Shares of LLY opened at $757.23 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market cap of $717.65 billion, a P/E ratio of 64.67, a P/E/G ratio of 1.40 and a beta of 0.48. The stock has a 50 day simple moving average of $797.84 and a two-hundred day simple moving average of $805.69. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the prior year, the company posted $2.58 earnings per share. The company's revenue was up 45.2% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Citigroup reduced their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. Finally, StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.